NTV Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
NTV Asset Management's CRSP Position: Q3 2026 in Review
NTV Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 61,443 shares worth $3.4M. The stake represents 0.31% of the portfolio and ranks #77 among its holdings.
502 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- NTV Asset Management held 61,443 shares of CRISPR Therapeutics worth $3.4M as of Q3 2026.
- CRISPR Therapeutics was a new NTV Asset Management position in Q3 2026.
- CRISPR Therapeutics made up 0.31% of NTV Asset Management's portfolio in Q3 2026, its #77 holding.
- 502 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on NTV Asset Management's 13F filing for Q3 2026, filed 23 Oct 2026.